eIF4E Inhibitor Compounds Targeting Protein-Protein Interaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders associated with eukaryotic initiation factor 4E (eIF4E, such as cancer, lack effective inhibitors that specifically target eIF4E, limiting therapeutic options.
Innovation Solution
Development of compounds, represented by Formula (I), which act as eIF4E inhibitors, forming pharmaceutically acceptable compositions to treat various diseases, including cancer, by binding to and inhibiting eIF4E activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for eIF4E-associated disorders, then existing therapeutic options are available, but they lack effective and specific eIF4E inhibition
Solution Approach 1:
The patent employs parameter changes by modifying molecular structure parameters to create compounds with optimized binding affinity and selectivity for eIF4E. The chemical structures are systematically varied to achieve the desired balance between therapeutic effectiveness and target specificity, transforming the molecular parameters to resolve the contradiction.
Solution Approach 2:
The invention uses structure-based design where compounds are designed to copy and mimic the cap-binding interface of eIF4E, allowing specific inhibition through structural mimicry. This copying approach enables the development of selective inhibitors that replicate the natural binding interactions while maintaining therapeutic effectiveness.
2Adaptability or versatility
If eIF4E inhibition is achieved through compound binding, then targeted therapy is provided, but the complexity of compound design and development increases
Solution Approach 1:
The patent applies segmentation by dividing the complex eIF4E binding interface into discrete molecular segments or pharmacophores. This segmentation allows for modular compound design where specific functional groups are optimized independently, reducing overall design complexity while maintaining targeted therapy capability.
Solution Approach 2:
The invention creates compounds with universal binding features that can interact with conserved residues across different eIF4E contexts. This multi-functionality approach allows a single compound design strategy to address multiple aspects of eIF4E inhibition, simplifying the development process while maintaining target specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit eIF4E activity, providing a therapeutic approach for treating eIF4E-associated disorders like cancer, offering a targeted mechanism for disease management.
Implementation Method 1
eIF4E binds to the 7-methylguanosine cap at the 5′ end of mRNAs, and forms a complex (called eIF4F) with the scaffolding protein eIF4G and the helicase eIF4A. The formation of this complex is required for the initiation of cap-dependent translation and therefore the binding of eIF4E to eIF4G is a critical event in this process.
Data Source
AI summary
The present invention provides compounds inhibiting eIF4E activity, and compositions and methods of using thereof. Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful for treating a variety of diseases, disorders or conditions, associated with eIF4E. Such diseases, disorders, or conditions include cellular proliferative disorders (e.g., cancer) such as those described herein.